isocarboxazid
Adjunctive therapy • Brands: Marplan
Last reviewed: 2025-12-30
General information
- Class: Adjunctive therapy
- Common US brands: Marplan
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2025-12-30
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Irreversible, nonselective monoamine oxidase inhibitor (MAOI). Generally reserved for treatment-resistant depression because of dietary restrictions and high-risk drug interaction profile (label/clinical).
Metabolism & Half‑life
- Metabolism: Not available (label)
- Half‑life: —
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- MARPLAN (isocarboxazid) tablets prescribing information — DailyMed (2023)
- Consensus recommendations for MAOI safety and dietary management — Journal of Clinical Psychopharmacology (2022)
- APA Clinical Practice Guideline for the Treatment of Depression — American Psychiatric Association (2023)
- CANMAT 2024 Clinical Guidelines for Major Depressive Disorder — Canadian Journal of Psychiatry (2024)